Consistent CV benefit and tolerability of SGLT2i in HF patients irrespective of diabetes
Media formats available:
Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!
Recommended
Subodh Verma, MD, PhD
Prof. Stephen Nicholls
- AHA 2019A rise in adverse clinical events with NOAC-regime after TAVR resulted in termination of trial
Prof. Freek Verheugt, MD